163 related articles for article (PubMed ID: 36610878)
21. Secondary Metastases Resection After Bevacizumab Plus Irinotecan-Based Chemotherapy in First-Line Therapy of Metastatic Colorectal Cancer in a Real-Life Setting: Results of the ETNA Cohort.
Rouyer M; Smith D; Laurent C; Becouarn Y; Guimbaud R; Michel P; Tubiana-Mathieu N; Balestra A; Jové J; Robinson P; Noize P; Moore N; Ravaud A; Fourrier-Réglat A;
Target Oncol; 2016 Feb; 11(1):83-92. PubMed ID: 26298481
[TBL] [Abstract][Full Text] [Related]
22. Effect of Neoadjuvant Chemotherapy Followed by Surgical Resection on Survival in Patients With Limited Metastatic Gastric or Gastroesophageal Junction Cancer: The AIO-FLOT3 Trial.
Al-Batran SE; Homann N; Pauligk C; Illerhaus G; Martens UM; Stoehlmacher J; Schmalenberg H; Luley KB; Prasnikar N; Egger M; Probst S; Messmann H; Moehler M; Fischbach W; Hartmann JT; Mayer F; Höffkes HG; Koenigsmann M; Arnold D; Kraus TW; Grimm K; Berkhoff S; Post S; Jäger E; Bechstein W; Ronellenfitsch U; Mönig S; Hofheinz RD
JAMA Oncol; 2017 Sep; 3(9):1237-1244. PubMed ID: 28448662
[TBL] [Abstract][Full Text] [Related]
23. Liver transplantation in a patient with unresectable colorectal liver metastases -- a case report.
Hrehoreţ D; Alexandrescu S; Braşoveanu V; Grigorie R; Zielinski C; Popescu I
Chirurgia (Bucur); 2013; 108(5):719-24. PubMed ID: 24157119
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness of liver metastasectomies in patients with metastatic colorectal cancer treated with FIr-B/FOx triplet chemotherapy plus bevacizumab.
Bruera G; Cannita K; Giuliante F; Lanfiuti Baldi P; Vicentini R; Marchetti P; Nuzzo G; Antonucci A; Ficorella C; Ricevuto E
Clin Colorectal Cancer; 2012 Jun; 11(2):119-26. PubMed ID: 22206922
[TBL] [Abstract][Full Text] [Related]
25. Adjuvant oxaliplatin- or irinotecan-containing chemotherapy improves overall survival following resection of metachronous colorectal liver metastases.
Liu JH; Hsieh YY; Chen WS; Hsu YN; Chau GY; Teng HW; King KL; Lin TC; Tzeng CH; Lin JK
Int J Colorectal Dis; 2010 Oct; 25(10):1243-9. PubMed ID: 20574727
[TBL] [Abstract][Full Text] [Related]
26. Surgical resection of hepatic and pulmonary metastases from colorectal carcinoma.
Shah SA; Haddad R; Al-Sukhni W; Kim RD; Greig PD; Grant DR; Taylor BR; Langer B; Gallinger S; Wei AC
J Am Coll Surg; 2006 Mar; 202(3):468-75. PubMed ID: 16500252
[TBL] [Abstract][Full Text] [Related]
27. Survival outcomes of liver metastasectomy in colorectal cancer cases: a single-center analysis in Turkey.
Cokmert S; Ellidokuz H; Demir L; Fuzun M; Astarcioglu I; Aslan D; Yilmaz U; Oztop I
Asian Pac J Cancer Prev; 2014; 15(13):5195-200. PubMed ID: 25040974
[TBL] [Abstract][Full Text] [Related]
28. Is Survival for Patients with Resectable Lung Metastatic Colorectal Cancer Comparable to Those with Resectable Liver Disease? Results from the South Australian Metastatic Colorectal Registry.
Patel D; Townsend AR; Karapetis C; Beeke C; Padbury R; Roy A; Maddern G; Roder D; Price TJ
Ann Surg Oncol; 2016 Oct; 23(11):3616-3622. PubMed ID: 27251133
[TBL] [Abstract][Full Text] [Related]
29. Population-based SEER analysis of survival in colorectal cancer patients with or without resection of lung and liver metastases.
Siebenhüner AR; Güller U; Warschkow R
BMC Cancer; 2020 Mar; 20(1):246. PubMed ID: 32293337
[TBL] [Abstract][Full Text] [Related]
30. Perioperative FOLFOX4 chemotherapy and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC 40983): long-term results of a randomised, controlled, phase 3 trial.
Nordlinger B; Sorbye H; Glimelius B; Poston GJ; Schlag PM; Rougier P; Bechstein WO; Primrose JN; Walpole ET; Finch-Jones M; Jaeck D; Mirza D; Parks RW; Mauer M; Tanis E; Van Cutsem E; Scheithauer W; Gruenberger T; ; ; ; ;
Lancet Oncol; 2013 Nov; 14(12):1208-15. PubMed ID: 24120480
[TBL] [Abstract][Full Text] [Related]
31. Real-World Outcomes of Oxaliplatin-Based Chemotherapy on R0 Resected Colonic Liver Metastasis.
Bosma NA; Cheung WY; Thiessen M; Speers C; Renouf DJ; Tilley D; Tang PA; Ball CG; Dixon E; Lee-Ying RM
Clin Colorectal Cancer; 2021 Sep; 20(3):e201-e209. PubMed ID: 34016533
[TBL] [Abstract][Full Text] [Related]
32. A multicentre study of capecitabine, oxaliplatin plus bevacizumab as perioperative treatment of patients with poor-risk colorectal liver-only metastases not selected for upfront resection.
Wong R; Cunningham D; Barbachano Y; Saffery C; Valle J; Hickish T; Mudan S; Brown G; Khan A; Wotherspoon A; Strimpakos AS; Thomas J; Compton S; Chua YJ; Chau I
Ann Oncol; 2011 Sep; 22(9):2042-2048. PubMed ID: 21285134
[TBL] [Abstract][Full Text] [Related]
33. Rate of Curative Surgery in Real-world Patients with Unresectable Metastatic Colorectal Cancer Treated with FOLFOXIRI ± Bevacizumab: A Western Canadian Province Experience.
Bhatti T; Moser M; Tan KT; Chalchal H; Souied O; Le D; Shaw J; Zaidi A; Gill D; Ahmed S
J Gastrointest Cancer; 2022 Jun; 53(2):427-433. PubMed ID: 33779898
[TBL] [Abstract][Full Text] [Related]
34. Hepatectomy Followed by Adjuvant Chemotherapy with 3-Month Capecitabine Plus Oxaliplatin for Colorectal Cancer Liver Metastases.
Satake H; Hashida H; Tanioka H; Miyake Y; Yoshioka S; Watanabe T; Matsuura M; Kyogoku T; Inukai M; Kotake T; Okita Y; Matsumoto T; Yasui H; Kotaka M; Kato T; Kaihara S; Tsuji A
Oncologist; 2021 Jul; 26(7):e1125-e1132. PubMed ID: 33977607
[TBL] [Abstract][Full Text] [Related]
35. Liver resection for colorectal cancer metastases.
Gallinger S; Biagi JJ; Fletcher GG; Nhan C; Ruo L; McLeod RS
Curr Oncol; 2013 Jun; 20(3):e255-65. PubMed ID: 23737695
[TBL] [Abstract][Full Text] [Related]
36. Tumor progression while on chemotherapy: a contraindication to liver resection for multiple colorectal metastases?
Adam R; Pascal G; Castaing D; Azoulay D; Delvart V; Paule B; Levi F; Bismuth H
Ann Surg; 2004 Dec; 240(6):1052-61; discussion 1061-4. PubMed ID: 15570210
[TBL] [Abstract][Full Text] [Related]
37. Treatment with bevacizumab and FOLFOXIRI in patients with advanced colorectal cancer: presentation of two novel trials (CHARTA and PERIMAX) and review of the literature.
Stein A; Glockzin G; Wienke A; Arnold D; Edelmann T; Hildebrandt B; Hollerbach S; Illerhaus G; Königsrainer A; Richter M; Schlitt HJ; Schmoll HJ
BMC Cancer; 2012 Aug; 12():356. PubMed ID: 22897915
[TBL] [Abstract][Full Text] [Related]
38. Intrahepatic Oxaliplatin and Systemic 5-FU +/- Cetuximab in Chemo-Naïve Patients with Liver Metastases from Colorectal Cancer.
Larsen FO; Jensen BV; Nørgaard HH; Hermann HK; Larsen PN; Markussen A; Hogdall E; Nielsen D
Oncology; 2019; 96(6):299-308. PubMed ID: 30999314
[TBL] [Abstract][Full Text] [Related]
39. Prognostic impact of immune response in resectable colorectal liver metastases treated by surgery alone or surgery with perioperative FOLFOX in the randomised EORTC study 40983.
Tanis E; Julié C; Emile JF; Mauer M; Nordlinger B; Aust D; Roth A; Lutz MP; Gruenberger T; Wrba F; Sorbye H; Bechstein W; Schlag P; Fisseler A; Ruers T
Eur J Cancer; 2015 Nov; 51(17):2708-17. PubMed ID: 26342674
[TBL] [Abstract][Full Text] [Related]
40. Tumour response and secondary resectability of colorectal liver metastases following neoadjuvant chemotherapy with cetuximab: the CELIM randomised phase 2 trial.
Folprecht G; Gruenberger T; Bechstein WO; Raab HR; Lordick F; Hartmann JT; Lang H; Frilling A; Stoehlmacher J; Weitz J; Konopke R; Stroszczynski C; Liersch T; Ockert D; Herrmann T; Goekkurt E; Parisi F; Köhne CH
Lancet Oncol; 2010 Jan; 11(1):38-47. PubMed ID: 19942479
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
